Hints and tips:
Related Topics
...In 2013, Ranbaxy Laboratories, once the country’s largest drugmaker, was fined $500m by the Department of Justice after pleading guilty to several charges....
...The Singh brothers, the Indian businessmen who once ran Ranbaxy Laboratories, have lost control of their business empire after being accused of siphoning off tens of millions of dollars from their biggest...
...In the most notorious case to date, New Delhi-based Ranbaxy Laboratories — once India’s largest drug company — was fined $500m in 2013 by the US Department of Justice after pleading guilty to seven criminal...
...Daiichi Sankyo has made a final exit from its problematic 2008 acquisition of Indian drugmaker Ranbaxy, selling its entire 8.9 per cent stake in India’s Sun Pharma, which completed a merger with Ranbaxy...
...Following the revocation of the six months exclusivity, the FDA granted approval to India’s Dr Reddy’s Laboratories, and US-based Endo International to launch generic versions of Valcyte....
...Ranbaxy accounted for a fifth of sales, but has produced a total net loss of Rs11.9bn since 2009....
...Sun Pharma is offering Ranbaxy shareholders 0.8 of its own stock for each Ranbaxy share, implying a price of Rs457 per Ranbaxy share compared with the Rs737 that Daiichi originally paid....
...Investors in Indian generic drug maker Sun Pharma are reacting positively to the company’s decision to buy out loss making rival Ranbaxy Laboratories in a $4bn deal....
...The deal with companies including Cipla and Ranbaxy Laboratories follows months of fierce debate over the price of Sovaldi, which has been hailed as the biggest breakthrough in treatment for hepatitis C...
...Ranbaxy said last year that more than $300m had been invested in upgrading its manufacturing facilities. But others suggest that Ranbaxy’s difficulties run deeper....
...Ranbaxy, acquired by Daiichi in 2008 for $4.7bn, has been struggling to overcome its troubled past....
...Something is very wrong at Ranbaxy Laboratories....
...The heightened vigilance comes in the wake of a scandal involving Ranbaxy, once India’s largest drugmaker, where a whistleblower revealed widespread falsification of data, eventually leading to criminal...
...In 2008, Japan’s Daiichi Sankyo paid $3.6bn for Ranbaxy Laboratories, India’s biggest drugmaker, though it later had to take a huge Y359bn ($3.6bn) writedown over the deal following problems with US regulators...
...Ranbaxy paid $500m in civil and criminal fines....
...Kohli said Ranbaxy was working towards the reopening of the facilities but warned this would not happen soon. Ranbaxy has been serving the US market from a single US facility, Ohm Laboratories....
...Last week Ranbaxy Laboratories, India’s biggest pharmaceuticals company, must have thought it had at last settled an eight-year dispute when it paid $500m in fines and compensation and pleaded guilty to...
...Shares in Indian generic drugs group Ranbaxy Laboratories dropped 4.2 per cent on Wednesday to Rs399.20, having lost 4 per cent in the previous session, after the company posted disappointing financial results...
...Q2 net loss at $85.3 million Ranbaxy Laboratories, India’s top drugmaker by sales, reported a net loss of 5.24 billion rupees for the June quarter on foreign exchange transactions and loss of goodwill booked...
...Related reading: Indian pharmaceutical groups shed copycat image, FT Wockhardt in India, FT Ranbaxy owners threaten to sue former investors over fine, FT India’s Ranbaxy: another can of worms, beyondbrics...
...Zydus began its search for original drugs in 2001 with the construction of a huge laboratory centre....
...: another can of worms Last week Ranbaxy Laboratories, India’s biggest pharmaceuticals company, must have thought it had at last settled an eight-year dispute when it paid $500m in fines and compensation...
...One year later, drugmaker Daiichi Sankyo took a $3.9bn writedown just months after taking control of generics manufacturer Ranbaxy Laboratories – one of the largest foreign deals involving an Indian company...
...It signals a fresh interest in co-operation and in expansion into the world’s lower income but faster-growing emerging markets, reflected in Daiichi Sankyo’s acquisition in 2008 of Ranbaxy, the Indian generics...
International Edition